Drugs / ABI-6250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06740474 | Jan → Jul 2025 | hepatitis D virus infection | Assembly Biosciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-08-06 | Assembly Biosciences | Results Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus assemblybio.com ↗ |
| 2025-05-07 | Assembly Biosciences | Results New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 assemblybio.com ↗
Our late-breaker poster highlights ABI-6250’s preclinical profile and potential as a once-daily oral therapy for chronic HDV infection, a severe form of viral hepatitis with limited treatment options available. |
| 2024-06-05 | Assembly Biosciences | Results Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024 assemblybio.com ↗
Results from preclinical evaluation included in this presentation demonstrate that ABI-6250 can effectively inhibit, at low nanomolar levels, HDV infection of the most prevalent genotypes (HDV-1,-2 and-3) in HepG2-NTCP cells. |
All press releases naming this drug 7 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-6250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06740474 ↗ |